ClinicalTrials.gg
CompletedNCT06241742Updated Mar 30, 2025

Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction

A Phase 2 interventional study of HT-6184 and HT-6184 Placebo in Pain, sponsored by Halia Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Halia Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Mar 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,882 studies in Pain with a site in United States — 313 open to participants now, 392 under way, 24 of them phase 3. Pain · United States.

Enrollment
1,119th of 2,560
81 · median 66
Started
2024
with 116 others
Phase 2
341 of 2,882
25 open now
Registered
2,556th of 2,882
by date

Among the 2,882 studies in Pain with a site in United States, this one is the 1,119th largest by enrollment of the 2,560 interventional ones that give a count, is one of 117 that started in 2024, is one of 341 in phase 2, and was the 2,556th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

313 of the 2,882 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

308 more — sign in →

All 313 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,882 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the ability of HT-6184 to decrease inflammation and pain in patients after third molar removal.

The main question it aims to answer are:

  • Does HT-6184 decrease inflammation in patients after third molar removal?
  • Does HT-6184 decrease pain in patients after third molar removal?

Participants will be asked to do the following during the clinical trial:

  • Take a single oral dose of HT-6184 or placebo
  • Allow a oral surgeon remove their third molar teeth
  • Blood draws on 5 occurrences
  • Rate their pain intensity
  • Attend two follow-up appointments on day 1 and day 2 after third molar removal
  • Participate in one follow-up phone call 5-7 days after third molar removal
03

Conditions studied

  • Pain

Keywords

  • third molar extraction
  • inflammation
  • biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The candidate is 18 years of age or older, capable of understanding and providing written to participate and willing to comply with study procedures including providing a blood sample to be saved for potential pharmacokinetic and/or genetic analysis.
  • The candidate, for any reason, requires surgical extraction of two or more third molars of which at least one is partially or fully impacted in mandibular bone.
  • The candidate is , surgically sterile or agrees to use an effective and medically acceptable method of for 1 week after his or her last dose of study drug.
  • If female with , the candidate must have a negative pregnancy test at screening and pre-surgery on the day of surgery.

Exclusion criteria

Exclusion Criteria:

  • The candidate typically or on average consumes more than one alcoholic beverage per day.
  • The candidate is pregnant or nursing.
  • The candidate has received an drug or used an experimental medical device within 30 days prior to screening.
  • The candidate has donated 1 or more pints of blood within 8 weeks prior to screening.
  • The candidate has any to components of the HT-6184/placebo formulations or the protocol-specified analgesic rescue medication, aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs).
  • The candidate has any to oral surgery or any serious or major medical problems that, in the investigator's opinion, may compromise the safety or the candidate or interfere with the interpretation of study results
  • The candidate has taken acetaminophen, NSAIDs (including aspirin) or other medications for pain within 72 hours of the surgical procedure.
  • The candidate has any abnormal laboratory value or physical finding that, in the opinion of the investigator, may compromise the individual's safety, interfere with interpretation of the study results, or be indicative of an underlying disease state.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Active comparator
    HT-6184 Treatment Arm

    Drug: HT-6184

  • Placebo comparator
    HT-6184 Placebo

    Drug: HT-6184 Placebo

Interventions

  • Single, oral dose of HT-6184

  • DrugHT-6184 Placebo

    Single, oral dose of placebo

06

What researchers measure

Primary outcomes

  1. Change in serum C-reactive protein levels from pre-dose

    Time frame: Up to 54 hours post surgery

  2. Incidence of adverse events

    Severity of AEs will be judged according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: Up to 7 days post surgery

  3. Incidence of serious adverse events

    Severity of AEs will be judged according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: Up to 7 days post surgery

Secondary outcomes

  1. Area under the categorical pain intensity-by-time curve (AUCs)

    Time frame: Up to 8 hours after surgery

07

Study locations

1 site
  • CenExel JBR
    Murray, Utah 84107, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Apr 2024, 2 months.

Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 2 months is below that.

Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2024
First posted
Feb 5, 2024
StartActual
Feb 12, 2024
Primary completionActual
Apr 30, 2024
CompletionActual
Apr 30, 2024
Results delay requested
Mar 13, 2025
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06241742
Lead sponsor
Halia Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 5, 2024
Start date
Feb 12, 2024
Primary completion
Apr 30, 2024
Completion
Apr 30, 2024
Last update
Mar 30, 2025

Study contacts

Halia Study Director
study director · Halia Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ofirnoflast

Start the discussion